Home

Account ⋅ Sign Out

Table of contents

Laryngeal cancer

What's new

Added 2022 ASCO, 2020 EHNS/ESMO, 2017 AAO-HNSF, 2016 ACS, and 2016 UKNMG guidelines for the diagnosis and management of laryngeal cancer.

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of laryngeal cancer are prepared by our editorial team based on guidelines from the American Society of Clinical Oncology (ASCO 2022,2018), the European Society for Radiotherapy and Oncology (ESTRO/EHNS/ESMO 2020), the American College of Radiology (ACR 2019), the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF 2017), the American Cancer...
Show more

Classification and risk stratification

Staging: as per EHNS/ESMO/ESTRO 2020 guidelines, Use the UICC TNM system for staging.
Create free account

Diagnostic investigations

History and physical examination: as per EHNS/ESMO/ESTRO 2020 guidelines, Obtain a clinical assessment in patients with suspected laryngeal cancer.
B

More topics in this section

  • Diagnostic imaging

Diagnostic procedures

Fine-needle aspiration
As per AAO-HNSF 2017 guidelines:
Perform FNA instead of open biopsy in patients with a neck mass of uncertain diagnosis deemed at increased risk for malignancy.
B
Continue evaluating patients with a cystic neck mass, as determined by FNA or imaging, until a diagnosis is obtained instead of assuming that the mass is benign.
B

More topics in this section

  • Tumor biopsy

  • Ancillary testing

Medical management

General principles: as per EHNS/ESMO/ESTRO 2020 guidelines, Manage patients with oropharyngeal cancer at high-volume facilities.
B
Show 3 more

More topics in this section

  • Management of locoregional disease (general principles)

  • Management of locoregional disease (induction chemotherapy)

  • Management of locoregional disease (primary surgery or radiotherapy)

  • Management of locoregional disease (postoperative chemoradiotherapy)

  • Management of locoregional disease (primary chemoradiotherapy)

  • Management of locoregional disease (elective neck dissection/irradiation)

  • Management of metastatic disease

  • Management of recurrent disease (locoregional disease)

  • Management of recurrent disease (advanced disease)

Nonpharmacologic interventions

Smoking cessation: as per ASCO 2018 guidelines, Encourage patients to abstain from smoking after the diagnosis and offer smoking cessation programs as necessary throughout and following treatment since continued cigarette smoking is associated with worse outcomes after therapy.
E

Therapeutic procedures

Technical considerations for radiotherapy
As per EHNS/ESMO/ESTRO 2020 guidelines:
Use intensity-modulated radiotherapy or volumetric-modulated arc therapy for radiotherapy.
A
Use a hypoxic radiosensitizer agent to increase locoregional control and disease-free survival.
A

Perioperative care

Perioperative voice and swallow assessment
As per ASCO 2018 guidelines:
Obtain a baseline assessment of voice and swallowing function as part of a comprehensive pretreatment evaluation to establish the functional impact of tumor volume and extent and stage of disease on voice and swallowing outcomes. Counsel patients about the potential effect of treatment options on voice, swallowing, and QoL.
B
Use the following instrumental, performance status, and quality-of-life measures of voice and swallowing to evaluate the pre- and post-treatment function:
self-recorded and/or expert-rated voice-quality measures
voice-related quality-of-life tools
videostroboscopy
radiographic (videofluoroscopic) or fiber-optic laryngoscopic evaluation of swallowing
dietary assessment
B

Follow-up and surveillance

Serial clinical assessment: as per ACS 2016 guidelines, Educate and counsel all head and neck cancer survivors about the signs and symptoms of local recurrence.
B
Show 4 more

More topics in this section

  • Serial endoscopic assessment

  • Serial imaging assessment

  • Survivorship and rehabilitation (lifestyle modifications)

  • Survivorship and rehabilitation (neuromuscular complications)

  • Survivorship and rehabilitation (neurosensory complications)

  • Survivorship and rehabilitation (speech disturbance)

  • Survivorship and rehabilitation (oral and dental care)

  • Survivorship and rehabilitation (gastroesophageal complications)

  • Survivorship and rehabilitation (thyroid dysfunction)

  • Survivorship and rehabilitation (lymphedema)

  • Survivorship and rehabilitation (fatigue)

  • Survivorship and rehabilitation (sleep disorders)

  • Survivorship and rehabilitation (psychosocial distress)